Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery

References

• Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat. Clin. Pract. Oncol.4(10), 578–590 (2007).
   PubMedGoogle Scholar
• Roukos DH. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N. Engl. J. Med.357(15), 1555–1556 (2007).
   PubMedGoogle Scholar
• Jemal A, Siegel R, Ward E et al. Cancer Statistics, 2008. CA Cancer J. Clin.58(2), 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Clarke M, Collins R, Darby S et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet366, 2087–2106 (2005).
   PubMed Web of Science ®Google Scholar
• Punglia RS, Morrow M, Winer EP, Harris JR. Local therapy and survival in breast cancer. N. Engl. J. Med.356(23), 2399–2405 (2007).
   PubMed Web of Science ®Google Scholar
• Arimidex Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group, Forbes JF, Cuzick J et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol.9(1), 45–53 (2008).
   PubMed Web of Science ®Google Scholar
• Tuttle TM, Habermann EB, Grund EH et al. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J. Clin. Oncol.25, 5203–5209 (2007).
   PubMed Web of Science ®Google Scholar
• Roukos DH. Linking contralateral breast cancer with genetics. Radiother. Oncol.86, 139–141 (2008).
   PubMedGoogle Scholar
• Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann. Oncol.18(7), 1133–1144 (2007).
   PubMed Web of Science ®Google Scholar
• Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol. Ther.6(3), 308–312 (2007).
   PubMed Web of Science ®Google Scholar
• Wood LD, Parsons DW, Jones S et al. The genomic landscapes of human breast and colorectal cancers. Science318(5853), 1108–1113 (2007).
   PubMed Web of Science ®Google Scholar
• International HapMap Consortium, Frazer KA, Ballinger DG et al. A second generation human haplotype map of over 3.1 million SNPs. Nature449(7164), 851–861 (2007).
   PubMed Web of Science ®Google Scholar
• Lee C, Morton CC. Structural genomic variation and personalized medicine. N. Engl. J. Med.358(7), 740–741 (2008).
   PubMedGoogle Scholar
• Korbel JO, Urban AE, Affourtit JP et al. Paired-end mapping reveals extensive structural variation in the human genome. Science318, 420–426 (2007).
   PubMed Web of Science ®Google Scholar
• Pennisi E. Breakthrough of the year. Human genetic variation. Science318(5858), 1842–1843 (2007).
   PubMed Web of Science ®Google Scholar
• Easton DF, Pooley KA, Dunning AM. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature447(7148), 1087–1093 (2007).
   PubMed Web of Science ®Google Scholar
• Gold B, Kirchhoff T, Stefanov Set al. Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc. Natl Acad. Sci. USA105(11), 4340–4345 (2008).
   PubMed Web of Science ®Google Scholar
• Hunter DJ, Kraft P, Jacobs KB et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet.39, 870–874 (2007).
   PubMed Web of Science ®Google Scholar
• Weir BA, Woo MS, Getz G et al. Characterizing the cancer genome in lung adenocarcinoma. Nature450(7171), 893–898 (2007).
   PubMed Web of Science ®Google Scholar
• Zheng SL, Sun J, Wiklund Fet al. Cumulative association of five genetic variants with prostate cancer. N. Engl. J. Med.358(9), 910–919 (2008).
   PubMed Web of Science ®Google Scholar
• McPherson R, Pertsemlidis A, Kavaslar N et al. A common allele on chromosome 9 associated with coronary heart disease. Science316(5830), 1488–1491 (2007).
   PubMed Web of Science ®Google Scholar
• Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, Novartis Institutes of Harvard and MIT, Lund University, Novartis Institutes of BioMedical Research et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science316(5829), 1331–1336 (2007).
   PubMed Web of Science ®Google Scholar
• Plenge RM, Seielstad M, Padyukov L et al. TRAF1-C5 as a risk locus for rheumatoid arthritis – a genomewide study. N. Engl. J. Med.357(12), 1199–1209 (2007).
   PubMed Web of Science ®Google Scholar
• Hom G, Graham RR, Modrek B et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N. Engl. J. Med.358(9), 900–909 (2008).
   PubMed Web of Science ®Google Scholar
• Weiss LA, Shen LA, Shen Y et al. Association between microdeletion and microduplication at 16p11.2 and autism. N. Engl. J. Med.358(7), 667–675 (2008).
   PubMed Web of Science ®Google Scholar
• Nguyen PL, Taghian AG, Katz MS et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J. Clin. Oncol.26(14), 2373–2378 (2008).
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER-2-positive breast cancer. N. Engl. J. Med.353, 1659–1672 (2005).
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2-positive breast cancer. N. Engl. J. Med.353, 1673–1684 (2005).
   PubMed Web of Science ®Google Scholar
• Fisher B. Biological and clinical considerations regarding the use of surgery and chemotherapy in the treatment of primary breast cancer. Cancer40(Suppl. 1), 574–587 (1977).
   PubMed Web of Science ®Google Scholar
• van de Vijver MJ, He YD, van’t Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med.347(25), 1999–2009 (2002).
   PubMed Web of Science ®Google Scholar
• Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J. Clin. Oncol.26(5), 721–728 (2008).
   PubMed Web of Science ®Google Scholar
• Hayes DF, Stearns V, Rae J, Flockhart D; Consortium on Breast Cancer Pharmacogenomics. A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients? J. Natl Cancer Inst.100(9), 610–613 (2008).
   Google Scholar
• Fisher B, Anderson S, Bryant J et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N. Engl. J. Med.347, 1233–1241 (2002).
   PubMed Web of Science ®Google Scholar
• Metcalfe K, Lynch HT, Ghadirian P et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol.22(12), 2328–2335 (2004).
   PubMed Web of Science ®Google Scholar
• Pierce LJ, Levin AM, Rebbeck TR et al. Ten-year multiinstitutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J. Clin. Oncol.24, 2437–2443 (2006).
   PubMed Web of Science ®Google Scholar
• Metcalfe KA, Lubinski J, Ghadirian Pet al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J. Clin. Oncol.26(7), 1093–1097 (2008).
   PubMed Web of Science ®Google Scholar
• Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann. Surg. Oncol.15, 21–33 (2008).
   PubMed Web of Science ®Google Scholar
• Narod SA, Offit K. Prevention and management of hereditary breast cancer. J. Clin. Oncol.23, 1656–1663 (2005).
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature434, 917–921 (2005).
   PubMed Web of Science ®Google Scholar
• Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell108, 171–182 (2002).
   PubMed Web of Science ®Google Scholar
• Roukos DH, Kappas AM, Tsianos E. Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann. Surg. Oncol.9(7), 607–609 (2002).
   PubMedGoogle Scholar
• Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann. Surg. Oncol.9(10), 941–943 (2002).
   PubMedGoogle Scholar
• Agnantis NJ, Paraskevaidis E, Roukos D. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann. Surg. Oncol.11(12), 1030–1034 (2004).
   PubMedGoogle Scholar
• Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian-cancer susceptibility gene BRCA1. Science266, 66–71 (1994).
   PubMed Web of Science ®Google Scholar
• Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature378, 789–792 (1995).
   PubMed Web of Science ®Google Scholar
• Smith P, McGuffog L, Easton DF et al. A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer45, 646–655 (2006).
   PubMed Web of Science ®Google Scholar
• Antoniou AC, Spurdle AB, Sinilnikova OM. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am. J. Hum. Genet.82(4), 937–948 (2008).
   PubMed Web of Science ®Google Scholar
• Antoniou AC, Sinilnikova OM, Simard J et al. RAD51 135G⊠C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am. J. Hum. Genet.81(6), 1186–1200 (2007).
   PubMed Web of Science ®Google Scholar
• Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat. Genet.31, 33–36 (2002).
   PubMed Web of Science ®Google Scholar
• Offit K, Garber JE. Time to check CHEK2in families with breast cancer? J. Clin. Oncol.26, 519–520 (2008).
   Google Scholar
• Friedman A, Perrimon N. Genetic screening for signal transduction in the era of network biology. Cell128(2), 225–231 (2007).
   PubMed Web of Science ®Google Scholar
• Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu. Rev. Cell Dev. Biol.23, 675–699 (2007).
   PubMed Web of Science ®Google Scholar
• Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol.3(1), 24–40 (2006).
   PubMedGoogle Scholar
• Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med.357(26), 2666–2676 (2007).
   PubMed Web of Science ®Google Scholar
• Patocs A, Zhang L, Xu Y et al. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N. Engl. J. Med.357, 2543–2551 (2007).
   PubMedGoogle Scholar
• Roukos DH. Breast-cancer stromal cells with TP53 mutations. N. Engl. J. Med.358(15), 1636 (2008).
   PubMedGoogle Scholar
• Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer7(11), 834–846 (2007).
   PubMed Web of Science ®Google Scholar
• Roukos DH. HER2 and response to paclitaxel in node-positive breast cancer. N. Engl. J. Med.358, 197 (2008).
   PubMedGoogle Scholar
• ENCODE Project Consortium, Birney E, Stamatoyannopoulos JA et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature447(7146), 799–816 (2007).
   PubMed Web of Science ®Google Scholar
• Kaiser J. Breakthrough of the year. It’s all about me. Science318(5858), 1843 (2007).
   PubMedGoogle Scholar
• Hunter DJ, Khoury MJ, Drazen JM. Letting the genome out of the bottle – will we get our wish? N. Engl. J. Med.358(2), 105–107 (2008).
   PubMed Web of Science ®Google Scholar
• Lakhani SR, Van De Vijver MJ, Jacquemier J et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, 59, 60 and p53 in patients with mutations in BRCA1 and BRCA2. J. Clin. Oncol.20, 2310–2318 (2002).
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Kelly Metcalfe K, Sun P et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin. Cancer Res.10, 2029–2034 (2004).
   PubMed Web of Science ®Google Scholar
• Kauff ND, Domchek SM, Friebel TM et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J. Clin. Oncol.26(8), 1331–1337 (2008).
   PubMed Web of Science ®Google Scholar
• Kaiser J. DNA sequencing. A plan to capture human diversity in 1000 genomes. Science319(5862), 395 (2008).
   Google Scholar
• Roukos DH, Lykoudis E, Liakakos T. Genomics and challenges toward personalized breast cancer local control. J. Clin. Oncol.26, DOI: 10.1200/JCO.2008.18.6197 (2008) (In press).
   Google Scholar
• Roukos DH. Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev. Mol. Diagn.8(1), 29–39 (2008).
   PubMed Web of Science ®Google Scholar